Lv1
40 积分 2025-07-11 加入
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
27天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications
1个月前
已完结
EHR development steps in long-term care
1个月前
已关闭
Rheumatoid arthritis
1个月前
已完结
Systemic lupus erythematosus
1个月前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
1个月前
已完结
Pathogenesis of autoimmune disease
1个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
2个月前
已完结
皖公网安备34019202002308
